Filing Flows › AbbVie (ABBV) › R&D spending
AbbVie (ABBV) R&D spending by quarter
AbbVie's R&D spending was $2.6B in Q3 2026 (third quarter 2026), +10% from Q2 2026. Over the last 7 quarters it ranged from $2.1B (Q1 2025) to $2.6B (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.6B | +10% | +11% |
| Q2 2026 | $2.3B | -5% | +10% |
| Q1 2026 | $2.5B | -4% | +20% |
| Q4 2025 | $2.6B | +11% | — |
| Q3 2025 | $2.3B | +9% | — |
| Q2 2025 | $2.1B | +3% | — |
| Q1 2025 | $2.1B | — | — |
Q3 2026 at a glance
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart follows the revenue to costs, profit and cash.
Questions
What is AbbVie's R&D spending?
AbbVie's R&D spending was $2.6B in Q3 2026 (third quarter 2026), +10% from Q2 2026.
How has AbbVie's R&D spending changed?
Over the last 7 quarters it ranged from $2.1B (Q1 2025) to $2.6B (Q4 2025).